Entrada Therapeutics Inc (TRDA) — Capital Reinvestment Ratio
Latest as of June 2024:
0.03x
Entrada Therapeutics Inc (TRDA) has a Capital Reinvestment Ratio of 0.03x as of June 2024, meaning it reinvests 0% of its operating cash flow ($39.83 Million) in capital expenditures ($1.05 Million). See Entrada Therapeutics Inc (TRDA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.03x
Capex / Operating Cash Flow
Operating Cash Flow
$39.83 Million
USD
Capital Expenditures
$1.05 Million
USD
Data as of
Jun 2024
Most recent filing
Entrada Therapeutics Inc Capital Reinvestment Ratio (2023–2023)
This chart tracks Entrada Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Entrada Therapeutics Inc (2023–2023)
Year-by-year Capital Reinvestment Ratio for Entrada Therapeutics Inc from 2023 to 2023. For live market cap and broader valuation context, see TRDA stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.04x | $139.80 Million | $5.61 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow